List of Tables
Table 1. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends
Table 2. Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers & Opportunity
Table 3. Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
Table 4. Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2020-2025)
Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Company (2020-2025) & (K Units)
Table 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Market Share by Company (2020-2025)
Table 9. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Price by Company (2020-2025) & (US$/Unit)
Table 10. Key Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base and Headquarters
Table 11. Key Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Chemotherapy Induced Peripheral Neuropathy Treatment
Table 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2024)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type (2020-2025) & (US$ Million)
Table 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type (2026-2031) & (US$ Million)
Table 19. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Type (2020-2025)
Table 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Type (2026-2031)
Table 21. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
Table 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Type (2020-2025) & (K Units)
Table 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Type (2026-2031) & (K Units)
Table 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Type (2020-2025)
Table 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Type (2026-2031)
Table 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2020-2025) & (US$/Unit)
Table 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2026-2031) & (US$/Unit)
Table 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application (2020-2025) & (US$ Million)
Table 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application (2026-2031) & (US$ Million)
Table 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Application (2020-2025)
Table 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Value by Application (2026-2031)
Table 33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
Table 34. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Application (2020-2025) & (K Units)
Table 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Application (2026-2031) & (K Units)
Table 36. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Application (2020-2025)
Table 37. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share in Volume by Application (2026-2031)
Table 38. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2020-2025) & (US$/Unit)
Table 39. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2026-2031) & (US$/Unit)
Table 40. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 41. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Region (2020-2025) & (US$ Million)
Table 42. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Region (2026-2031) & (US$ Million)
Table 43. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Region (2020-2025) & (%)
Table 44. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Region (2026-2031) & (%)
Table 45. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
Table 46. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Region (2020-2025) & (K Units)
Table 47. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Region (2026-2031) & (K Units)
Table 48. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Region (2020-2025) & (%)
Table 49. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Region (2026-2031) & (%)
Table 50. Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Region (2020-2025) & (US$/Unit)
Table 51. Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Region (2026-2031) & (US$/Unit)
Table 52. Key Countries/Regions Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 53. Key Countries/Regions Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value, (2020-2025) & (US$ Million)
Table 54. Key Countries/Regions Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value, (2026-2031) & (US$ Million)
Table 55. Key Countries/Regions Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume, (2020-2025) & (K Units)
Table 56. Key Countries/Regions Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume, (2026-2031) & (K Units)
Table 57. Aptinyx Inc Company Information
Table 58. Aptinyx Inc Introduction and Business Overview
Table 59. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 60. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 61. Aptinyx Inc Recent Development
Table 62. Asahi Kasei Pharma Corp Company Information
Table 63. Asahi Kasei Pharma Corp Introduction and Business Overview
Table 64. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 65. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 66. Asahi Kasei Pharma Corp Recent Development
Table 67. Regenacy Pharmaceuticals Company Information
Table 68. Regenacy Pharmaceuticals Introduction and Business Overview
Table 69. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 70. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 71. Regenacy Pharmaceuticals Recent Development
Table 72. MAKScientific LLC Company Information
Table 73. MAKScientific LLC Introduction and Business Overview
Table 74. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 76. MAKScientific LLC Recent Development
Table 77. Metys Pharmaceuticals AG Company Information
Table 78. Metys Pharmaceuticals AG Introduction and Business Overview
Table 79. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 81. Metys Pharmaceuticals AG Recent Development
Table 82. Nemus Bioscience Inc Company Information
Table 83. Nemus Bioscience Inc Introduction and Business Overview
Table 84. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 85. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 86. Nemus Bioscience Inc Recent Development
Table 87. PledPharma Company Information
Table 88. PledPharma Introduction and Business Overview
Table 89. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 91. PledPharma Recent Development
Table 92. Sova Pharmaceuticals Inc Company Information
Table 93. Sova Pharmaceuticals Inc Introduction and Business Overview
Table 94. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 95. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 96. Sova Pharmaceuticals Inc Recent Development
Table 97. DermaXon LLC Company Information
Table 98. DermaXon LLC Introduction and Business Overview
Table 99. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 100. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 101. DermaXon LLC Recent Development
Table 102. Kineta Inc Company Information
Table 103. Kineta Inc Introduction and Business Overview
Table 104. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 105. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 106. Kineta Inc Recent Development
Table 107. Krenitsky Pharmaceuticals Inc Company Information
Table 108. Krenitsky Pharmaceuticals Inc Introduction and Business Overview
Table 109. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 110. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 111. Krenitsky Pharmaceuticals Inc Recent Development
Table 112. PeriphaGen Company Information
Table 113. PeriphaGen Introduction and Business Overview
Table 114. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 115. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 116. PeriphaGen Recent Development
Table 117. Apexian Pharma Company Information
Table 118. Apexian Pharma Introduction and Business Overview
Table 119. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 120. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 121. Apexian Pharma Recent Development
Table 122. WinSanTor Company Information
Table 123. WinSanTor Introduction and Business Overview
Table 124. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 125. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Offerings
Table 126. WinSanTor Recent Development
Table 127. Key Raw Materials Lists
Table 128. Raw Materials Key Suppliers Lists
Table 129. Chemotherapy Induced Peripheral Neuropathy Treatment Downstream Customers
Table 130. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Product Picture
Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (2020-2031) & (US$ Million)
Figure 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume (2020-2031) & (K Units)
Figure 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price (2020-2031) & (US$/Unit)
Figure 6. Chemotherapy Induced Peripheral Neuropathy Treatment Report Years Considered
Figure 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Players Revenue Ranking (2024) & (US$ Million)
Figure 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Players Sales Volume Ranking (2024) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Chemotherapy Induced Peripheral Neuropathy Treatment Revenue in 2024
Figure 10. Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 11. Calcium Channel α2-delta Ligands Picture
Figure 12. Antidepressants Picture
Figure 13. Opioids Picture
Figure 14. Others Picture
Figure 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Market Share by Type, 2024 & 2031
Figure 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
Figure 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Market Share by Type, 2024 & 2031
Figure 19. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2020-2031) & (US$/Unit)
Figure 20. Product Picture of Platinum Agents
Figure 21. Product Picture of Taxanes
Figure 22. Product Picture of Vinca Alkaloids
Figure 23. Product Picture of Others
Figure 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value Market Share by Application, 2024 & 2031
Figure 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
Figure 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Market Share by Application, 2024 & 2031
Figure 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2020-2031) & (US$/Unit)
Figure 29. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (2020-2031) & (US$ Million)
Figure 30. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Country (%), 2024 VS 2031
Figure 31. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value, (2020-2031) & (US$ Million)
Figure 32. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Country (%), 2024 VS 2031
Figure 33. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value, (2020-2031) & (US$ Million)
Figure 34. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Region (%), 2024 VS 2031
Figure 35. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value, (2020-2031) & (US$ Million)
Figure 36. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Country (%), 2024 VS 2031
Figure 37. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value, (2020-2031) & (US$ Million)
Figure 38. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Country (%), 2024 VS 2031
Figure 39. Key Countries/Regions Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (%), (2020-2031)
Figure 40. Key Countries/Regions Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume (%), (2020-2031)
Figure 41. United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value, (2020-2031) & (US$ Million)
Figure 42. United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type (%), 2024 VS 2031
Figure 43. United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application (%), 2024 VS 2031
Figure 44. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value, (2020-2031) & (US$ Million)
Figure 45. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type (%), 2024 VS 2031
Figure 46. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application (%), 2024 VS 2031
Figure 47. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value, (2020-2031) & (US$ Million)
Figure 48. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type (%), 2024 VS 2031
Figure 49. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application (%), 2024 VS 2031
Figure 50. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value, (2020-2031) & (US$ Million)
Figure 51. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type (%), 2024 VS 2031
Figure 52. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application (%), 2024 VS 2031
Figure 53. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value, (2020-2031) & (US$ Million)
Figure 54. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type (%), 2024 VS 2031
Figure 55. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application (%), 2024 VS 2031
Figure 56. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value, (2020-2031) & (US$ Million)
Figure 57. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type (%), 2024 VS 2031
Figure 58. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application (%), 2024 VS 2031
Figure 59. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value, (2020-2031) & (US$ Million)
Figure 60. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Type (%), 2024 VS 2031
Figure 61. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value by Application (%), 2024 VS 2031
Figure 62. Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain
Figure 63. Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Cost Structure
Figure 64. Channels of Distribution (Direct Sales, and Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
